OBJECTIVES: Diabetic Macular Edema (DME) is a leading cause of vision loss and blindness. The aim of the study is the evaluation of the benefits concerning the introduction of an additional alternative technology, Dexamethasone intravitreal implant (DEX), in comparison with the present scenario consisting of the repeated administration of intravitreal injections of Ranibizumab. They differ for the number of injections and adverse events (AEs) occurring after each therapeutic cycle. METHODS: An HTA was conducted within 3 Italian Departments of Ophthalmology, in Lombardy Region. Qualitative and quantitative data were collected using specific validated questionnaires and self-reported interviews, applying a MCDA approach and considering 7 dimensions resulting from the EUnetHTA Core Model. RESULTS: At the 36 month time point of the base-case scenario for market penetration, the introduction of DEX could lead to i) significant economic savings to the Regional Health Service (-15%), even considering the AEs impacts (14.82% severe AEs for Ranibizumab vs